Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | CCR9 | P51686 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198946 | 0.89 | CCR2 (0.71) | CCR2ABCB11CCR9 | |
| SCHEMBL4217582 | 0.88 | CCR2 (0.70) | CCR2ABCB11CCR9 | |
| SCHEMBL6302546 | 0.87 | CCR2 (1.00) | CCR2ABCB11 | |
| SCHEMBL4206942 | 0.86 | CCR2 (0.68) | CCR2ABCB11CCR9 | |
| SCHEMBL13802525 | 0.86 | CCR2 (0.71) | CCR2ABCB11CCR9 | |
| SCHEMBL4537700 | 0.86 | CCR2 (0.76) | CCR2ABCB11 | |
| SCHEMBL3205608 | 0.85 | CCR2 (0.63) | CCR2ABCB11CCR9 | |
| SCHEMBL3209668 | 0.85 | CCR2 (0.74) | CCR2ABCB11 | |
| SCHEMBL4208025 | 0.85 | CCR2 (0.74) | CCR2ABCB11CCR9 | |
| SCHEMBL27658570 | 0.84 | CCR2 (0.82) | CCR2ABCB11CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009063495-A2 | SUBSTITUTED INDOLE AND ITS DERIVATIVES AS CANNABINOID MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2009-05-22 | — | — | WO | claimed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2009063495-A2 | SUBSTITUTED INDOLE AND ITS DERIVATIVES AS CANNABINOID MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | CCR2 1386/4885ABCB11 529/4885CCR9 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.